| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PHAT | Common Stock | Sale | $551,843 | -17,269 | -1.3% | $31.96 | 1,323,676 | 19 May 2021 | David A. Socks 2013 Revocable Trust | F1, F2 |
| transaction | PHAT | Common Stock | Sale | $525,193 | -16,020 | -1.2% | $32.78 | 1,307,656 | 19 May 2021 | David A. Socks 2013 Revocable Trust | F3 |
| transaction | PHAT | Common Stock | Sale | $107,783 | -3,229 | -0.25% | $33.38 | 1,304,427 | 19 May 2021 | David A. Socks 2013 Revocable Trust | F4 |
| transaction | PHAT | Common Stock | Sale | $30,351 | -899 | -0.07% | $33.76 | 1,303,528 | 20 May 2021 | David A. Socks 2013 Revocable Trust | F5 |
| transaction | PHAT | Common Stock | Sale | $79,580 | -2,278 | -0.17% | $34.93 | 1,301,250 | 20 May 2021 | David A. Socks 2013 Revocable Trust | F6 |
| transaction | PHAT | Common Stock | Sale | $10,756 | -305 | -0.02% | $35.27 | 1,300,945 | 20 May 2021 | David A. Socks 2013 Revocable Trust | F7 |
| holding | PHAT | Common Stock | 103 | 19 May 2021 | By 401(k) Plan |
| Id | Content |
|---|---|
| F1 | All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $33.28. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.32 to $33.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $34.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.23 to $35.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.23 to $35.41. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |